Umbilical Cord Blood As A Regulated Source Of Starting Material
Source: Cell & Gene
Did you know that umbilical cord blood is an FDA-approved source of starting material for cell therapies? In this segment from the Cell & Gene Live digital event Stem-Cell Derived Therapies: From Source To Site, Colleen Delaney, MD, Founder, CSO, EVP of R&D at Deverra Therapeutics, and CSO and CMO at Coeptis Therapeutics, makes the case for using cord blood as a starting material for stem cells and stem-cell derived therapies. She also touches on the scalability of cord blood in pooled donor manufacturing.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
This website uses cookies to ensure you get the best experience on our website. Learn more